Immuno-oncology innovations redefining cancer treatment in 2024

By Taylor Mixides (Drug Target Review)2024-01-23T09:10:53

In this exclusive interview, Dr Espen Basmo Ellingsen, a luminary in cancer immunology, provides insights into the anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member